Literature DB >> 12536224

Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro.

Robert Veerhuis1, Mariëlle J Van Breemen, Jeroen M Hoozemans, Michela Morbin, Jamal Ouladhadj, Fabrizio Tagliavini, Piet Eikelenboom.   

Abstract

Pro-inflammatory cytokines released by activated microglia could be a driving force in Alzheimer's disease (AD) pathology. We evaluated whether the presence of complement factor C1q and serum amyloid P component (SAP) in Abeta deposits is related to microglial activation. Activated microglia accumulate in SAP- and C1q-immunoreactive fibrillar amyloid beta (Abeta) plaques in AD temporal cortex. No clustered microglia are seen in SAP- and C1q-positive circumscript, non-fibrillar, tau-negative Abeta plaques in AD caudate nucleus and non-demented control temporal cortex. In addition, no clustered microglia were observed in C1q- and SAP-negative, irregular shaped, diffuse plaques in AD caudate nucleus and in non-demented control temporal cortex, which suggests that microglia are attracted and activated in Abeta deposits of certain fibrillarity that, in addition, have fixed SAP and C1q. Therefore, the effects of Abeta(1-42), SAP and C1q on cytokine secretion by human postmortem microglia in vitro were assessed. Abeta(1-42) alone had little to no effect. Abeta(1-42) peptides in combination with C1q or C1q and SAP increased microglial interleukin (IL)-6 secretion four- and eightfold, respectively. Tumor necrosis factor (TNF)-alpha, as well as intracellular IL-1alpha and IL-1beta levels, also increased upon exposure of microglia to Abeta(1-42)-SAP-C1q complexes. Combined with earlier findings, that amyloid and activated microglia accumulate at a relatively early stage of cognitive decline in AD patients, this suggests that clustering of activated, cytokine-secreting microglia in SAP- and C1q-containing Abeta deposits precedes neurodegenerative changes in AD, and thus may provide a "therapeutic window".

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12536224     DOI: 10.1007/s00401-002-0624-7

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  36 in total

1.  Evidence for three loci modifying age-at-onset of Alzheimer's disease in early-onset PSEN2 families.

Authors:  Elizabeth E Marchani; Thomas D Bird; Ellen J Steinbart; Elisabeth Rosenthal; Chang-En Yu; Gerard D Schellenberg; Ellen M Wijsman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-07       Impact factor: 3.568

2.  Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity.

Authors:  Izumi Maezawa; Pavel I Zimin; Heike Wulff; Lee-Way Jin
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

Review 3.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

4.  Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Authors:  Simon E Kolstoe; Basil H Ridha; Vittorio Bellotti; Nan Wang; Carol V Robinson; Sebastian J Crutch; Geoffrey Keir; Riitta Kukkastenvehmas; J Ruth Gallimore; Winston L Hutchinson; Philip N Hawkins; Stephen P Wood; Martin N Rossor; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

Review 5.  Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation.

Authors:  Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  Haptoglobin modulates beta-amyloid uptake by U-87 MG astrocyte cell line.

Authors:  Bernardetta Maresca; Maria Stefania Spagnuolo; Luisa Cigliano
Journal:  J Mol Neurosci       Date:  2014-11-18       Impact factor: 3.444

7.  Goodpasture antigen-binding protein/ceramide transporter binds to human serum amyloid P-component and is present in brain amyloid plaques.

Authors:  Chiara Mencarelli; Gerard H Bode; Mario Losen; Mahesh Kulharia; Peter C Molenaar; Robert Veerhuis; Harry W M Steinbusch; Marc H De Baets; Gerry A F Nicolaes; Pilar Martinez-Martinez
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

Review 8.  Microglia in neurodegenerative disease.

Authors:  V Hugh Perry; James A R Nicoll; Clive Holmes
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

Review 9.  Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding.

Authors:  Wendy Noble; Claire J Garwood; Diane P Hanger
Journal:  Prion       Date:  2009-04-21       Impact factor: 3.931

Review 10.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.